Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,255
datasets available to search
ShareScore release 0.9.0
Dataset results
3,255 results for “Pancreatic Cancer”
A Pancreas Organoids-based Screen Identifies a Specific KRAS Mutation Inhibitor that Attenuating Cholesterol Biosynthesis Pathway in Pancreatic Cancer
GEO Series GSE207352. Mus musculus. 4 samples. Type: Expression profiling by high throughput sequencing.
Oxidative Stress-Induced Immunogenic Cell Death Enhances Whole-Cell Vaccine Efficacy in a Syngeneic Pancreatic Cancer Model
GEO Series GSE316213. Mus musculus. 2 samples. Type: Expression profiling by high throughput sequencing.
RNA-seq in pancreatic cancer PANC1 cells
GEO Series GSE131126. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Epigenome Mapping in ING3-silenced pancreatic cancer cells
GEO Series GSE140711. Homo sapiens. 4 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Biological characteristics of gene expression features in pancreatic cancer cell induced by proton and x-ray irradiation IV
GEO Series GSE107443. Homo sapiens. 8 samples. Type: Expression profiling by array.
IRE1α Downregulation Enhances STING-Mediated Chemoresistance and Guides Precision Therapies in Pancreatic Cancer
GEO Series GSE284365. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing; Other.
KRAS Inhibition Activates an Actionable CD24 “Don’t Eat Me” Signal in Pancreatic Cancer
GEO Series GSE305316. Mus musculus. 24 samples. Type: Expression profiling by high throughput sequencing.
CRISPR Screen identifies regulators for T cells activities in pancreatic cancer
GEO Series GSE254334. Mus musculus. 2 samples. Type: Other.
LNCRNA expression in pancreatic cancer tissues
GEO Series GSE278515. Homo sapiens. 6 samples. Type: Expression profiling by array; Non-coding RNA profiling by array.
Differentially expressed genes of C2C12 cells influenced by murine pancreatic cancer derived exosomes
GEO Series GSE174058. Mus musculus. 2 samples. Type: Expression profiling by array.
Transcriptome changes after knocking out MYEOV in two human pancreatic cancer cell lines
GEO Series GSE143827. Homo sapiens. 11 samples. Type: Expression profiling by high throughput sequencing.
Dataset related to article "Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND)."
<p><strong>Aim:</strong> Regorafenib may be active in different cancer types. This Phase II trial included patients with various refractory cancer types treated with regorafenib. Here, we report the results of the pancreatic adenocarcinoma cohort. <strong>Methods:</strong> The primary end point was progression-free survival (PFS) rate at 8 weeks; further investigation of regorafenib would be warranted with a PFS rate ≥50%. <strong>Results:</strong> A total of 20 patients were enrolled. The best response was stable disease in four patients (20%). The 8-week PFS rate was 25% with a median PFS of 1.7 months (95% CI: 1.5-2.0). A total of 13 patients (65%) experienced grade 3-4 treatment-related adverse events. <strong>Conclusion:</strong> The study did not meet its primary end point. Further investigation of regorafenib monotherapy in this setting is not recommended. <strong>Clinical Trial Registration:</strong> <a href="http://clinicaltrials.gov/show/NCT02307500">NCT02307500</a>.</p>
Link to dataset related to article "FOXA2 controls the cis-regulatory networks of pancreatic cancer cells in a differentiation grade-specific manner."
<p>Differentiation of normal and tumor cells is controlled by regulatory networks enforced by lineage-determining transcription factors (TFs). Among them, TFs such as FOXA1/2 bind naïve chromatin and induce its accessibility, thus establishing new gene regulatory networks. Pancreatic ductal adenocarcinoma (PDAC) is characterized by the coexistence of well- and poorly differentiated cells at all stages of disease. How the transcriptional networks determining such massive cellular heterogeneity are established remains to be determined. We found that FOXA2, a TF controlling pancreas specification, broadly contributed to the cis-regulatory networks of PDACs. Despite being expressed in both well- and poorly differentiated PDAC cells, FOXA2 displayed extensively different genomic distributions and controlled distinct gene expression programs. Grade-specific functions of FOXA2 depended on its partnership with TFs whose expression varied depending on the differentiation grade. These data suggest that FOXA2 contributes to the regulatory networks of heterogeneous PDAC cells via interactions with alternative partner TFs.</p>
Dataset related to article "Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells"
<p>This record contains data related to the article "Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells".</p> <p>Better understanding of pancreatic diseases, including pancreatic ductal adenocarcinoma (PDAC), is an urgent medical need, with little advances in preoperative differential diagnosis, preventing rational selection of therapeutic strategies. The clinical management of pancreatic cancer patients would benefit from the identification of variables distinctively associated with the multiplicity of pancre- atic disorders. We investigated, by 1H nuclear magnetic resonance, the metabolomic fingerprint of pancreatic juice (the biofluid that collects pancreatic products) in 40 patients with different pancreatic diseases. Metabolic variables discriminated PDAC from other less aggressive pancreatic diseases and identified metabolic clusters of patients with distinct clinical behaviors. PDAC specimens were overtly glycolytic, with significant accumulation of lactate, which was probed as a disease-specific variable in pancreatic juice from a larger cohort of 106 patients. In human PDAC sections, high expression of the glucose transporter GLUT-1 correlated with tumor grade and a higher density of PD-1+ T cells, suggesting their accumulation in glycolytic tumors. In a preclinical model, PD-1+ CD8 tumor–infiltrating lymphocytes differentially infiltrat- ed PDAC tumors obtained from cell lines with different metabolic consumption, and tumors metabolically rewired by knocking down the phosphofructokinase (Pfkm) gene displayed a decrease in PD-1+ cell infiltration. Collectively, we introduced pancreatic juice as a valuable source of metabolic variables that could contri- bute to differential diagnosis. The correlation of metabolic markers with immune infiltration suggests that upfront evaluation of the metabolic profile of PDAC patients could foster the introduction of immunotherapeutic approaches for pancreatic cancer.</p> <p> </p>
Dataset related to article "Oncogenic KRAS-Induced Protein Signature in the Tumor Secretome Identifies Laminin-C2 and Pentraxin-3 as Useful Biomarkers for the Early Diagnosis of Pancreatic Cancer "
<p>This record contains raw data related to article “Oncogenic KRAS-Induced Protein Signature in the Tumor Secretome Identifies Laminin-C2 and Pentraxin-3 as Useful Biomarkers for the Early Diagnosis of Pancreatic Cancer"</p> <p>Abstract</p> <p><em>KRAS</em> mutations characterize pancreatic cell transformation from the earliest stages of carcinogenesis, and are present in &gt;95% of pancreatic ductal adenocarcinoma (PDAC) cases. In search of novel biomarkers for the early diagnosis of PDAC, we identified the proteins secreted by the normal human pancreatic cell line (HPDE) recently transformed by inducing the overexpression of the <em>KRAS<sup>G12V</sup></em> oncogene. We report a proteomic signature of <em>KRAS</em>-induced secreted proteins, which was confirmed in surgical tumor samples from resected PDAC patients. The putative diagnostic performance of three candidates, Laminin-C2 (LAMC2), Tenascin-C (TNC) and Pentraxin-3 (PTX3), was investigated by ELISA quantification in two cohorts of PDAC patients (<em>n</em> = 200) eligible for surgery. Circulating levels of LAMC2, TNC and PTX3 were significantly higher in PDAC patients compared to the healthy individuals (<em>p</em> &lt; 0.0001). The Receiver Operating Characteristics (ROC) curve showed good sensitivity (1) and specificity (0.63 and 0.85) for LAMC2 and PTX3, respectively, but not for TNC, and patients with high levels of LAMC2 had significantly shorter overall survival (<em>p</em> = 0.0007). High levels of LAMC2 and PTX3 were detected at early stages (I-IIB) and in CA19-9-low PDAC patients. In conclusion, pancreatic tumors release LAMC2 and PTX3, which can be quantified in the systemic circulation, and may be useful in selecting patients for further diagnostic imaging.</p>
Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With Locally Advanced Pancreatic Cancer (PANOVA-3CA)
ClinicalTrials.gov study NCT07319910. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
ClinicalTrials.gov study NCT01017822. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
ClinicalTrials.gov study NCT00253526. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies
ClinicalTrials.gov study NCT00081549. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity
GEO Series GSE194249. Homo sapiens. 87 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.